A Phase 1/2 interventional study of RMC-6236 in Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by Revolution Medicines, Inc.. Recruiting at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Revolution Medicines, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. — 8 open to participants now, 9 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Revolution Medicines, Inc..
Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc., this one has the largest planned enrollment, is one of 2 that started in 2022, is one of 5 in phase 1/2, and was the 5th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. are open now, in 12 countries. Recruiting first, the newest first:
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Australia, Belgium and 16 more countries
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Australia, Austria and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 6 · Phase 3 2
First in 2018; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 754 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 430 across the 13 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Revolution Medicines, Inc. is the lead sponsor of 20 studies on the registry; 13 are open to participants now.
4 of the studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06040541Revolution Medicines, Inc.Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | 2026-12-31 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT05379985Revolution Medicines, Inc.Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | 2027-05-31 |
| NCT06162221Revolution Medicines, Inc.Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
This is a Phase 1/2, multicenter open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and clinical activity of escalating doses of RMC-6236 in adult patients with advanced solid tumors harboring specific RAS mutations, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose [RP2D] within investigated patient population groups. RMC-6236 is a potent, orally bioavailable RAS-MULTI(ON) inhibitor, selective for the active RAS(ON) form of both wild type and mutant variants of the canonical RAS isoforms (HRAS, NRAS, and KRAS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations. Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, Melanoma, gynecological cancer or other solid tumors not previously specified). RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61)
Drug: RMC-6236
Oral Tablets
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs
Time frame: up to 2.5 years
Number of Participants with Dose-Limiting Toxicity (DLT)
Time frame: 21 days
Maximum Observed Blood Concentration (Cmax) of RMC-6236
Time frame: up to 15 weeks
Time to Reach Maximum Blood Concentration (Tmax) of RMC-6236
Time frame: up to 15 weeks
Area Under Blood Concentration Time Curve (AUC) of RMC-6236
Time frame: up to 15 weeks
Elimination Half-Life of RMC-6236 (t1/2)
Time frame: up to 15 weeks
Ratio of accumulation of RMC-6236 from a single dose to steady state with repeated dosing
Time frame: up to 15 weeks
Overall Response Rate (ORR)
Overall response rate per RECIST v1.1
Time frame: up to 2.5 years
Duration of Response (DOR)
Duration of response per RECIST v1.1
Time frame: up to 2.5 years
Disease Control Rate (DCR)
Disease control rate per RECIST v1.1
Time frame: up to 2.5 years
Time to Response (TTR)
Time to response per RECIST v1.1
Time frame: up to 2.5 years
Progression-Free Survival (PFS)
Progression-free survival per RECIST v1.1
Time frame: up to 2.5 years
Started May 2022 (actual). Primary completion is estimated for May 2027, 60 months after the start.
Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 60 months is close to that.
Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daraxonrasib
Carcinoma, Non-Small-Cell Lung →